Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.47

+0.3%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3082)	3/14/2001 5:09:20 PM
From: Jibacoa	Read Replies (1) of 52153

Yes,and the company only uses 16.661 million shares in their computations. Also it is interesting to see that in spite of having a $39.619 million operating loss for the year (including in-process R&D) they finished with more than $307 million extra in cash. It seems the Common offering was a very profitable one although it was not reflected in the stock price as, (except for the "January effect), the down trend has been pretty well preserved since November: siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next